Plasma Factor VII May Increase the Sensitivity and Specifiicity of the APRI Score in Seperating Mild and Significant Fibrosis in Patients with Hepatitis C

R Hawari,N Snyder,SY Xiao,J Peterson

DOI: https://doi.org/10.14309/00000434-200509001-00353

2005-01-01

Abstract:Purpose: Separating mild from significant fibrosis is an important step in the decision making process in treating and evaluating the prognosis of HCV patients. Liver biopsy remains the gold standard. The APRI*. is a recently proposed index (Wai et al. Hepatology; 38:518–526) that we have found to be accurate in both a retrospective and prospective study of patients with HCV undergoing liver biopsy at our institution. Cutoffs of ≤0.42 and ≥1.2 accurately identified patients with mild and significant fibrosis (Snyder et al Gastroenterol 126:A-304, Snyder et al Am J Gastroenterol 99 S100–101). Rodríguez-Iñigo et al, found that the percentage of hepatocytes expressing Factor VII was significantly lower in stage 4 liver fibrosis patients than in stage 3, stage 2, stage 1 and stage 0 patients (P < 0.001). (Blood Coagulation & Fibrinolysis, 12:193). We hypothesized that addition of Facto VII measurement might enhance the sensitivity of the APRI. *APRI = AST/ULN × 100/platelets(109/L) Methods: The patients studied were 19 patients with chronic HCV undergoing pretreatment liver biopsies. Patients were excluded if they had received anti-viral treatment within the last year, if they were co infected with HBV or HIV, or had an organ transplants. All patients had blood drawn on the day of the biopsy. The Factor VII assay was run on the STA-R instrument (Diagnostic Stago Parsippany, NJ.) The APRI was calculated. The liver biopsies were read blindly by one pathologist using the Ludwig Batts criteria for staging of fibrosis. Analysis was performed using Insightful Miner 2 software (Insightful Corporation Seattle, WA.). Results: One patient had an inadequate biopsy and two other patients did not have Factor VII measured because of inadequate specimen. Based on the biopsy results, there were 13 patients with significant fibrosis (F2–F4) and 5 patients with mild fibrosis (F0–F1). By logistic regression, the APRI had a sensitivity of 84.6% and a specificity of 60%. The combination of the APRI and Factor VII resulted in an improved sensitivity of 100% and a specificity of 100% in separating patients with significant fibrosis from patients with mild fibrosis. Conclusions: Factor VII measurement may improve the sensitivity and the specificity of the APRI score in separating mild and significant fibrosis in patients with HCV. A larger number of patients is needed to evaluate this further.